Stay updated on Enfortumab Vedotin Combinations in Urothelial Cancer Clinical Trial
Sign up to get notified when there's something new on the Enfortumab Vedotin Combinations in Urothelial Cancer Clinical Trial page.

Latest updates to the Enfortumab Vedotin Combinations in Urothelial Cancer Clinical Trial page
- Check6 days agoNo Change Detected
- Check13 days agoChange DetectedThe page now shows that recruitment is closed for the study and introduces new navigation/help sections (How to Read a Study Record, Common Questions, How to Join a Study) while standardizing the Interventions heading to 'Intervention/Treatment' and updating the revision tag to v3.6.0, replacing the prior v3.5.5.SummaryDifference0.2%

- Check20 days agoChange DetectedThe page revision was updated from v3.5.4 to v3.5.5, indicating a minor update to the page's documentation/versioning rather than changes to the visible content.SummaryDifference0.0%

- Check27 days agoChange DetectedFooter metadata and indexing terms were expanded to include IPD sharing, FDA-regulated status, and additional related terms for indexing and search. No core study content or eligibility criteria were altered.SummaryDifference100%

- Check34 days agoChange DetectedCore sections including the Study Overview, locations and contacts, and study status were removed, leaving less information about the EV-103 urothelial cancer trial.SummaryDifference20%

- Check41 days agoChange DetectedThe page’s revision tag was updated from v3.5.3 to v3.5.4, signaling a version update to the study record page rather than a substantive content change.SummaryDifference0.0%

- Check63 days agoChange DetectedThe page’s revision/version indicator has been updated from v3.5.2 to v3.5.3.SummaryDifference0.0%

Stay in the know with updates to Enfortumab Vedotin Combinations in Urothelial Cancer Clinical Trial
Enter your email address, and we'll notify you when there's something new on the Enfortumab Vedotin Combinations in Urothelial Cancer Clinical Trial page.